keyword
MENU ▼
Read by QxMD icon Read
search

ESMO guideline

keyword
https://www.readbyqxmd.com/read/30113631/esmo-consensus-conference-on-testicular-germ-cell-cancer-diagnosis-treatment-and-follow-up
#1
F Honecker, J Aparicio, D Berney, J Beyer, C Bokemeyer, R Cathomas, N Clarke, G Cohn-Cedermark, G Daugaard, K-P Dieckmann, K Fizazi, S Fosså, J R Germa-Lluch, P Giannatempo, J A Gietema, S Gillessen, H S Haugnes, A Heidenreich, K Hemminki, R Huddart, M A S Jewett, F Joly, J Lauritsen, A Lorch, A Necchi, N Nicolai, C Oing, J Oldenburg, D Ondruš, A Papachristofilou, T Powles, A Sohaib, O Ståhl, T Tandstad, G Toner, A Horwich
The European Society for Medical Oncology (ESMO) consensus conference on testicular cancer was held on 3-5 November 2016 in Paris, France. The conference included a multidisciplinary panel of 36 leading experts in the diagnosis and treatment of testicular cancer (34 panel members attended the conference; an additional two panel members [CB and K-PD] participated in all preparatory work and subsequent manuscript development). The aim of the conference was to develop detailed recommendations on topics relating to testicular cancer that are not covered in detail in the current ESMO Clinical Practice Guidelines (CPGs) and where the available level of evidence is insufficient...
August 3, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/30105234/management-of-hormone-receptor-positive-human-epidermal-receptor-2-negative-advanced-or-metastatic-breast-cancers
#2
REVIEW
Roger K C Ngan
Hormone therapy, rather than chemotherapy, is recommended for hormone-receptor positive (HR+), human epidermal receptor 2 negative (HER2-) advanced or metastatic breast cancer (A/MBC) according to the European Society of Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO) and National Comprehensive Cancer Network (NCCN) guidelines, unless in visceral crisis in which chemotherapy is indicated. Hormonal monotherapy of selective estrogen receptor modulator (SERM) or selective estrogen receptor down-regulator (SERD), aromatase inhibitor (AI), or their combination as doublets, used to be the mainstay options as first-line (1L) therapy for most patients...
July 2018: Annals of Translational Medicine
https://www.readbyqxmd.com/read/30094071/challenge-of-implementing-clinical-practice-guidelines-getting-esmo-s-guidelines-even-closer-to-the-bedside-introducing-the-esmo-practising-oncologists-checklists-and-knowledge-and-practice-questions
#3
EDITORIAL
Stefan Rauh, Dirk Arnold, Sofia Braga, Razvan Curca, Robert Eckert, Ana Fröbe, Michalis Karamouzis, Gabor Lakatos, Jean-Luc Molitor
No abstract text is available yet for this article.
2018: ESMO Open
https://www.readbyqxmd.com/read/30052758/management-of-cancer-pain-in-adult-patients-esmo-clinical-practice-guidelines
#4
M Fallon, R Giusti, F Aielli, P Hoskin, R Rolke, M Sharma, C I Ripamonti
No abstract text is available yet for this article.
July 24, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/30037178/robot-assisted-extended-lymphadenectomy-in-prostate-cancer
#5
Stavros I Tyritzis, Nikolaos Kalampokis, Nikolaos Grivas, Henk G van der Poel, N Peter Wiklund
INTRODUCTION: The extent of lymph node dissection (LND) and its potential survival benefit are still a matter of debate. Aim of our review was to summarize the latest literature data regarding the surgical templates, the potential oncological benefits, the functional outcomes and the complications of extended lymph node dissection (eLND) during robot-assisted radical prostatectomy (RARP). EVIDENCE ACQUISITION: We systematically reviewed all relevant studies using PubMed, MEDLINE, Embase, American Urological Association (AUA), European Society of Medical Oncology (ESMO) and European Association of Urology (EAU) guidelines...
July 23, 2018: Minerva Chirurgica
https://www.readbyqxmd.com/read/30032243/4th-eso-esmo-international-consensus-guidelines-for-advanced-breast-cancer-abc-4
#6
F Cardoso, E Senkus, A Costa, E Papadopoulos, M Aapro, F André, N Harbeck, B Aguilar Lopez, C H Barrios, J Bergh, L Biganzoli, C B Boers-Doets, M J Cardoso, L A Carey, J Cortés, G Curigliano, V Diéras, N S El Saghir, A Eniu, L Fallowfield, P A Francis, K Gelmon, S R D Johnston, B Kaufman, S Koppikar, I E Krop, M Mayer, G Nakigudde, B V Offersen, S Ohno, O Pagani, S Paluch-Shimon, F Penault-Llorca, A Prat, H S Rugo, G W Sledge, D Spence, C Thomssen, D A Vorobiof, B Xu, L Norton, E P Winer
No abstract text is available yet for this article.
July 19, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/30016389/diagnosis-assessment-and-management-of-constipation-in-advanced-cancer-esmo-clinical-practice-guidelines
#7
P J Larkin, N I Cherny, D La Carpia, M Guglielmo, C Ostgathe, F Scotté, C I Ripamonti
No abstract text is available yet for this article.
July 17, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29992308/delirium-in-adult-cancer-patients-esmo-clinical-practice-guidelines
#8
S H Bush, P G Lawlor, K Ryan, C Centeno, M Lucchesi, S Kanji, N Siddiqi, A Morandi, D H J Davis, M Laurent, N Schofield, E Barallat, C I Ripamonti
No abstract text is available yet for this article.
July 10, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29982402/waldenstr%C3%A3-m-s-macroglobulinaemia-esmo-clinical-practice-guidelines-for-diagnosis-treatment-and-follow-up
#9
E Kastritis, V Leblond, M A Dimopoulos, E Kimby, P Staber, M J Kersten, A Tedeschi, C Buske
No abstract text is available yet for this article.
July 5, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29970548/efficacy-safety-of-facilitated-subcutaneous-immunoglobulin-in-immunodeficiency-due-to-hematological-malignancies-a-single-center-retrospective-analysis
#10
Maria Dimou, Theodore Iliakis, Dimitrios Maltezas, Aikaterini Bitsani, Sotiria Kalyva, Aspasia Koudouna, Sotiria Kotsanti, Panayiota Petsa, Paraskevi Papaioannou, Marie-Christine Kyrtsonis, Panayiotis Panayiotidis
BACKGROUND/AIM: Hematological malignancies are frequently complicated by secondary immunodeficiency (SID). Immunoglobulin replacement with intravenous gamma globulins (IVIg) reduces infection incidence, antibiotics' need and hospitalization days in these patients. Facilitated subcutaneous immunoglobulin replacement (fSCIg) has been studied in primary immunodeficiency patients and is equally efficacious with several advantages (self-administration, same bioavailability, long infusion intervals, fewer adverse drug reactions)...
July 2018: Anticancer Research
https://www.readbyqxmd.com/read/29951306/a-review-of-guidelines-for-lung-cancer
#11
REVIEW
Paolo Bironzo, Massimo Di Maio
Clinical practice guidelines include recommendations intended to optimize patient care. In the last years, the introduction of immune checkpoint inhibitors is rapidly changing lung cancer management and therefore guidelines are essential to assist clinicians in such an evolving field. We reviewed the recommendations about the use of these immune checkpoint inhibitors in clinical practice guidelines issued by three scientific societies [European Society of Medical Oncology (ESMO); American Society of Clinical Oncology (ASCO); Italian Association of Medical Oncology (AIOM)] and one not-for-profit U...
May 2018: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/29931177/diarrhoea-in-adult-cancer-patients-esmo-clinical-practice-guidelines
#12
P Bossi, A Antonuzzo, N I Cherny, O Rosengarten, S Pernot, F Trippa, U Schuler, A Snegovoy, K Jordan, C I Ripamonti
No abstract text is available yet for this article.
June 21, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29924296/esmo-consensus-conference-on-malignant-lymphoma-management-of-ultra-high-risk-patients
#13
M Hutchings, M Ladetto, C Buske, P de Nully Brown, A J M Ferreri, M Pfreundschuh, N Schmitz, A Sureda Balari, G van Imhoff, J Walewski
The European Society for Medical Oncology (ESMO) consensus conference on malignant lymphoma was held on 20 June 2015 in Lugano, Switzerland, and included a multidisciplinary panel of 25 leading experts. The aim of the conference was to develop recommendations on critical subjects difficult to consider in detail in the ESMO Clinical Practice Guidelines. The following areas were identified: (1) the elderly patient, (2) prognostic factors suitable for clinical use and (3) the 'ultra-high-risk' group. Before the conference, the expert panel was divided into three working groups; each group focused on one of these areas in order to address clinically relevant questions relating to that topic...
June 19, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29917046/management-of-toxicities-from-immunotherapy-esmo-clinical-practice-guidelines-for-diagnosis-treatment-and-follow-up
#14
J B A G Haanen, F Carbonnel, C Robert, K M Kerr, S Peters, J Larkin, K Jordan
No abstract text is available yet for this article.
June 15, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29912434/evidence-based-optimization-of-post-treatment-surveillance-for-skull-base-chordomas-based-on-local-and-distant-disease-progression
#15
Jacob L Freeman, Ascher B Kaufmann, Richard G Everson, Franco DeMonte, Shaan M Raza
BACKGROUND: There are no guidelines regarding post-treatment surveillance specific to skull base chordomas. OBJECTIVE: To determine an optimal imaging surveillance schedule to detect both local and distant metastatic skull base chordoma recurrences. METHODS: A retrospective review of 91 patients who underwent treatment for skull base chordoma between 1993 and 2017 was conducted. Time to and location of local and distant recurrence(s) were cataloged...
April 18, 2018: Operative Neurosurgery (Hagerstown, Md.)
https://www.readbyqxmd.com/read/29878045/primary-cutaneous-lymphomas-esmo-clinical-practice-guidelines-for-diagnosis-treatment-and-follow-up
#16
R Willemze, E Hodak, P L Zinzani, L Specht, M Ladetto
No abstract text is available yet for this article.
June 6, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29863118/comparison-of-the-guidelines-for-colorectal-cancer-in-japan-the-usa-and-europe
#17
REVIEW
Takahide Shinagawa, Toshiaki Tanaka, Hiroaki Nozawa, Shigenobu Emoto, Koji Murono, Manabu Kaneko, Kazuhito Sasaki, Kensuke Otani, Takeshi Nishikawa, Keisuke Hata, Kazushige Kawai, Toshiaki Watanabe
Colorectal cancer (CRC) is one of the most common cancers globally as well as in Japan and has shown a pattern of increasing incidence and mortality rates. Therefore, guidelines for CRC are considered to be crucial for establishing standard medical treatment not only in Japan but also around the world. In this article, we explain the features of the representative guidelines in Japan (Japanese Society for Cancer of the Colon and Rectum [JSCCR]), the USA (National Comprehensive Cancer Network [NCCN]) and Europe (European Society for Medical Oncology [ESMO]) and review the differences among these guidelines for CRC...
January 2018: Annals of gastroenterological surgery
https://www.readbyqxmd.com/read/29846513/gastrointestinal-stromal-tumours-esmo-euracan-clinical-practice-guidelines-for-diagnosis-treatment-and-follow-up
#18
P G Casali, N Abecassis, S Bauer, R Biagini, S Bielack, S Bonvalot, I Boukovinas, J V M G Bovee, T Brodowicz, J M Broto, A Buonadonna, E De Álava, A P Dei Tos, X G Del Muro, P Dileo, M Eriksson, A Fedenko, V Ferraresi, A Ferrari, S Ferrari, A M Frezza, S Gasperoni, H Gelderblom, T Gil, G Grignani, A Gronchi, A Hannu, B Hassan, P Hohenberger, R Issels, H Joensuu, R L Jones, I Judson, P Jutte, S Kaal, B Kasper, K Kopeckova, D A Krákorová, A Le Cesne, I Lugowska, O Merimsky, M Montemurro, M A Pantaleo, R Piana, P Picci, S Piperno-Neumann, A L Pousa, P Reichardt, M H Robinson, P Rutkovski, A A Safwat, P Schöffski, S Sleijfer, S Stacchiotti, K Sundby Hall, M Unk, F Van Coevorden, W Van der Graaf, J Whelan, E Wardelmann, O Zaikova, J Y Blay
No abstract text is available yet for this article.
May 28, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29846498/soft-tissue-and-visceral-sarcomas-esmo-euracan-clinical-practice-guidelines-for-diagnosis-treatment-and-follow-up
#19
P G Casali, N Abecassis, S Bauer, R Biagini, S Bielack, S Bonvalot, I Boukovinas, J V M G Bovee, T Brodowicz, J M Broto, A Buonadonna, E De Álava, A P Dei Tos, X G Del Muro, P Dileo, M Eriksson, A Fedenko, V Ferraresi, A Ferrari, S Ferrari, A M Frezza, S Gasperoni, H Gelderblom, T Gil, G Grignani, A Gronchi, A Hannu, B Hassan, P Hohenberger, R Issels, H Joensuu, R L Jones, I Judson, P Jutte, S Kaal, B Kasper, K Kopeckova, D A Krákorová, A Le Cesne, I Lugowska, O Merimsky, M Montemurro, M A Pantaleo, R Piana, P Picci, S Piperno-Neumann, A L Pousa, P Reichardt, M H Robinson, P Rutkovski, A A Safwat, P Schöffski, S Sleijfer, S Stacchiotti, K Sundby Hall, M Unk, F Van Coevorden, W Van der Graaf, J Whelan, E Wardelmann, O Zaikova, J Y Blay
No abstract text is available yet for this article.
May 28, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29843143/the-role-of-salvage-high-dose-chemotherapy-in-relapsed-male-germ-cell-tumors
#20
Christoph Oing, Anja Lorch
Germ cell tumors (GCT) are a unique tumor entity with excellent cure rates if guideline-endorsed treatment is thoroughly applied. Even patients with widespread metastatic disease can often be cured with cisplatin-based combination chemotherapy as part of a multimodal treatment approach. However, about 30% of patients with metastatic disease at initial presentation, corresponding to about 5-10% of all GCT patients, relapse or progress despite first-line treatment and therefore require salvage chemotherapy. Salvage systemic treatment either consists of conventional-dose cisplatin-based combination chemotherapy or sequential high-dose treatment with carboplatin and etoposide plus subsequent autologous stem cell support...
2018: Oncology Research and Treatment
keyword
keyword
170239
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"